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We read with interest the recent review by Tilg et al.1, which summarised the role of microbiota in 
liver diseases and pointed out that a causal link with systemic inflammation has still not been 
established. This letter fills in this gap and provides an analysis of the circulating microbiota in portal 
vein as the link between gut and liver. The access to portal circulation is possible during the 
implantation of a transjugular intrahepatic portosystemic shunt (TIPS). Therefore, we characterized 
the circulating microbiome in portal vein (first venous outflow in gut-liver-axis), liver outflow, central 
venous blood, and peripheral venous blood from 7 patients with decompensated liver cirrhosis 
receiving TIPS for either variceal bleeding (n=3) or refractory ascites (n=4) (mean MELD 8.4 [range 6-
13], CHILD A n=4, CHILD B n=3) (Figure 1A). We performed 16S ribosomal RNA (rRNA) gene 
sequencing of buffy coat samples and identified 65 genera belonging to 4 phyla (predominantly 
Proteobacteria) in this cohort (Supplementary Figure 1 and Figure 1B). Blood microbiome phylum 
compositions identified in our study agreed with previous findings investigating the peripheral blood 
microbiome in buffy-coat samples from liver fibrosis patients2 as well as healthy individuals3, but 
differed from the gut microbiome measured in fecal samples, where Bacteroidetes and Firmicutes 
are predominant2. 
Although overall bacterial community structure did not show a compartment-specific clustering as 
assessed by Bray-Curtis dissimilarity measures (Figure 1C), the abundance of several genera varied 
strongly in circulation forming compartment-specific patterns (Figure 1D, using DESeq2 for 
differential abundance analysis4). To verify whether the bacteria observed in 16S rRNA gene 
sequencing were viable in blood, we performed aerobic and anaerobic cultivation of blood from the 
four sites of five additional TIPS patients. Three out of five patients showed positive cultivation with 
Staphylococcus and one that showed bacterial growth of Acinetobacter, both abundant in the 
sequencing data (Supplementary Figure 1). These results demonstrate that circulating microbiota are 
indeed viable. 
Bacterial infections are frequent in cirrhotics, often trigger acute-on-chronic liver failure and are 
associated with high mortality5. A number of cytokines, which might show immune dysfunction, 
systemic inflammation and oxidative stress have been linked to decompensation, acute-on-chronic 
liver failure and mortality6–10. 
To elaborate on the relationship with systemic inflammation, we measured cytokine levels in serum 
of the same patients and compartments except central venous blood. Inflammatory cytokines 
formed patient-specific clusters (Figure 2A) and their individual measurements showed robust 
associations with the abundance of blood microbiome genera measured by Spearman correlation 
(Figure 2B), which establish the association of circulating microbiota with systemic inflammation.  
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To the best of our knowledge, this study is the first to track the major part of microbiome of portal-
venous blood through liver into central venous blood and circulating into peripheral blood. With this 
study we provide snapshots of the circulating blood microbiome, its compartment-specific patterns, 
viability of the microbial members and their association with inflammation. Further studies with 
larger cohorts are required to better understand the role of circulating microbiome and expand the 
knowledge about gut microbiome contribution to liver diseases reviewed recently1. 
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Figures 
 
 Figure 1. A) During implantation of a transjugular portosystemic shunt (TIPS), central, hepatic and 
portal venous blood, as well as peripheral blood, was collected from 7 patients. B) Phylum 
composition of buffy coat samples from different compartments. C) Microbial community 
compositions did not differ significantly between compartment. D) Differentially abundant genera in 
the cohort. Portal, hepatic and central (Atrium) venous blood microbiome were compared to that of 
peripheral blood.  
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Figure 2. A) Cytokine levels were patient-specific and the clustering was driven by IP-10 (CXCL-10) 
and IL-1ra. Relative abundance of 65 identified genera in portal, hepatic and central venous, as well 
as peripheral blood. Heatmaps show relative abundance (scale showed on the right). Genera absent 
in a sample are marked by white boxes. B) Spearman correlations between microbial genus 
abundance and inflammatory markers. Only statistically significant correlations (adjusted P < 0.05) 
are shown.  
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Supplemental Figure 1. Relative abundance of 65 identified genera in portal, hepatic and central venous, as 
well as peripheral blood from cohort A. Heatmaps show relative abundance (scale showed on the right). 
Genera absent in a sample are marked by white boxes. 
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